Andrew Asa Hindman M.B.A — Chief Business Development Officer at Acorda Therapeutics

Mr. Andrew Asa Hindman, M.B.A has been the Chief Business Development Officer of Acorda Therapeutics, Inc. since May 13, 2014 and serves as its Head of Financial Planning and Analysis & Investor Relations. Mr. Hindman served several senior executive level positions in the biopharmaceutical industry. Mr. Hindman served as the Chief Executive Officer and President of Tobira Therapeutics, Inc. since April 2011. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams and raising operating capital. Mr. Hindman served as Senior Vice President of Corporate Development at Nodality, Inc. since joining in May 2010. He served as Vice President of Corporate Development at Onyx Pharmaceuticals since August 2008. During his tenure, he helped build a world-class corporate development capability, executed strategic partnerships and led the acquisition of Proteolix. Previously, Mr. Hindman served at Gilead Sciences as the Senior Director of Alliance Management and over his ten years with Nodality, Inc., held a series of positions with increasing responsibility within Corporate Development, Commercial Operations and Government Affairs. During his tenure, he led the global launch of Hepsera and helped lead the merger with NeXstar Pharmaceuticals. Prior to Gilead, he helped establish the biotechnology investment banking franchise at J.P. Morgan. He has been Director of Biotie Therapies Corp. since December 2016. He served as Director of Tobira Therapeutics, Inc. Mr. Hindman holds an MBA from Columbia University and a BA in Biochemistry and Economics, with High Honors from Wesleyan University.